Compare BCAL & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAL | VALN |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.7M | 582.2M |
| IPO Year | 2020 | 2021 |
| Metric | BCAL | VALN |
|---|---|---|
| Price | $21.13 | $5.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $24.75 | $12.28 |
| AVG Volume (30 Days) | ★ 154.2K | 16.3K |
| Earning Date | 10-28-2026 | 11-24-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 777.27 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.29 | N/A |
| Revenue Next Year | $6.46 | $87.84 |
| P/E Ratio | $16.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.87 | $4.75 |
| 52 Week High | $22.59 | $12.18 |
| Indicator | BCAL | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 41.89 |
| Support Level | $20.60 | $5.16 |
| Resistance Level | $22.00 | $5.52 |
| Average True Range (ATR) | 0.50 | 0.20 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 18.42 | 7.36 |
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.